AUGUST - 20239TECH OUTLOOKthe insulin-producing cells in the first place, a potential cure for diabetes that would eliminate the need for ongoing treatment of the condition.What Can Your Organization Do to Prepare?My team at Advarra continues to support amazing researchers in academia and biopharma in advancing these novel therapies through clinical development stage and into the clinic.Is your organization ready for what is coming next? · New manufacturing systems will need to be developed and installed. · Distribution systems built around genetically engineered biologics designed specifically for one patient will take the place of mass-produced pill bottles. · Bench research labs will need advanced gene editing tools and biochemists looking at cells rather than small molecule chemical compositions. · Medical professionals will need to be trained and understand how these new immunotherapies work and when to prescribe them. · And most importantly, patients with debilitating conditions will expect these therapies to be available to them when they need it and at a location which is convenient for them.It is indeed an exciting time to be involved in the clinical research field! We see immunotherapy intersecting with gene editing to potentially cure previously incurable conditions and as researchers continue to explore the potential of immunotherapy, we're starting to see innovative applications beyond just the oncology field
< Page 8 | Page 10 >